Marcal

Quick links to important sections

Marcal

Method of action: Mineral, Mineral Supplements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Marcal

What is Marcal?

Marcal is a pharmacological treatment utilized in the management of calcium and vitamin D levels within the body. It is classified as a mineral and vitamin supplement, typically composed of calcium carbonate and cholecalciferol (vitamin D3). These two components work in coordination to support bone health and metabolic functions.

Primary Components

  • Calcium Carbonate: This is a mineral salt that provides a high concentration of elemental calcium. Calcium is essential for the structural integrity of the skeletal system, nerve transmission, and muscle function.
  • Cholecalciferol (Vitamin D3): This fat-soluble vitamin facilitates the intestinal absorption of calcium. Without sufficient vitamin D, the body cannot effectively utilize the calcium provided through diet or supplementation.

Mechanism of Action

The primary function of Marcal is to maintain calcium homeostasis. When blood calcium levels are low, the body may draw calcium from the bones to support vital functions, which can lead to weakened bone structure over time. By providing a supplemental source of calcium and enhancing its absorption through vitamin D3, Marcal helps ensure that the body has an adequate supply of these nutrients, thereby supporting bone density and strength.

Clinical Applications

Marcal is commonly used in several clinical contexts where calcium or vitamin D levels are insufficient. These include:

  • Prevention and Management of Bone Disorders: It is frequently used as an adjunct therapy for conditions characterized by bone loss, such as osteoporosis or osteomalacia.
  • Addressing Deficiencies: It is used to treat or prevent calcium and vitamin D deficiencies that may arise due to dietary limitations, age-related changes, or specific health conditions.
  • Supportive Care: It may be recommended for individuals with increased nutritional requirements, such as the elderly, to help reduce the risk of fractures.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Marcal?

Possible Side Effects and Safety Information

The officially documented safety profile for Marcal (Calcium Acetate) is primarily characterized by effects on the gastrointestinal system and the risk of mineral imbalance related to the drug's composition as a calcium salt. This information is derived from government regulatory documents, such as the FDA and EMA prescribing labels.


Adverse Reaction Classification

Classification Examples of Adverse Reactions (Label-Documented)
Very Common Hypercalcemia (elevated calcium levels), Nausea, Diarrhea
Common Vomiting
System-Organ Class Gastrointestinal Disorders; Metabolism and Nutrition Disorders
Frequency Not Known Dizziness, Edema (swelling), Weakness

Serious Adverse Reactions and Safety Constraints

The most significant safety concern listed in official documents is Hypercalcemia, which is classified as a very common and potentially serious adverse reaction. Severe Hypercalcemia may be associated with symptoms such as confusion, delirium, and coma, and chronic exposure may contribute to long-term issues like vascular and soft-tissue calcification.

Safety Restrictions: The medication is contraindicated in patients with a pre-existing condition of elevated blood calcium (Hypercalcemia). Regulatory labels advise that concurrent use of other calcium supplements should be avoided.

Population Safety Notes: Official labeling notes that maintaining normal serum calcium levels is crucial for pregnant and breastfeeding individuals, as hypercalcemia in the mother may be associated with risks to the fetus. The safety and efficacy of the medication have not been established in pediatric patients.

Exposure Patterns: Regulatory documents specify that the risk of progressive Hypercalcemia is dose-related and requires blood calcium monitoring during initial dosage adjustment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Marcal (Calcium Acetate) is defined by the development of progressive hypercalcemia, a condition resulting from the administration in excess of the appropriate daily dosage. Regulatory documents classify the manifestations based on severity, corresponding to measured serum calcium levels.

Documented Overdose Presentations

Mild Hypercalcemia (serum calcium 10.5 to 11.9 mg/dL) may present with non-specific gastrointestinal symptoms, including constipation, anorexia, nausea, and vomiting.

Severe Hypercalcemia (serum calcium 12 mg/dL) is associated with serious central nervous system effects, such as confusion, delirium, stupor, and coma. This severe state may also precipitate cardiac arrhythmias, especially in patients concurrently taking digitalis. Chronic overdose resulting in uncontrolled calcium levels may lead to vascular and soft-tissue calcification.

Required Emergency Actions

The official guidance mandates that patients with symptoms indicating a life-threatening outcome—such as collapse, trouble breathing, or inability to be awakened—must call emergency services immediately. Overdose management necessitates the discontinuation of therapy. For severe cases, the initiation of emergency measures including acute hemodialysis may be required. No specific antidote is documented; treatment is supportive. Monitoring of serum calcium levels is required twice weekly during management.

Therapeutic Uses of Marcal

The fundamental purpose of Marcal (Calcium Acetate) is to provide therapeutic support in managing the severe metabolic consequences of advanced kidney failure. Its use is applied in addressing the persistent mineral imbalance that characterizes this chronic disease state.

Calcium Acetate is used to help manage high blood levels of phosphorus in people with kidney disease who are on dialysis, a function associated with the clinical purpose of phosphate binders.


Primary Indications and Therapeutic Benefits

Marcal is commonly used to address hyperphosphatemia—the clinical condition of having excessively high levels of phosphorus in the blood, which is generally experienced by patients with End-Stage Renal Disease (ESRD) and those undergoing dialysis. The primary therapeutic scope is applied to address high blood phosphorus, and plays a role in assisting with the risk of vascular calcification and the management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). This provides support for long-term health management. Controlling the mineral imbalance may assist with providing a direct supportive benefit against related symptomatic patterns.


Quick Fact Block

Quick Fact: Support for Systemic Symptoms Description
Primary Indication Hyperphosphatemia (High blood phosphorus)
Long-Term Support Assists with mitigating the risk of vascular calcification and CKD-MBD progression.
Assists with Symptom Management May assist with the relief of uremic pruritus (severe itching) and muscle cramping.
Usage Context Applied in chronic management for patients with advanced kidney disease on dialysis.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Marcal?

The eligibility for using Marcal (Calcium Acetate) is strictly defined by regulatory guidelines, focusing on the target population, absolute contraindications, and specific patient risk factors.


Eligibility Profile

Classification Status and Population
Standard Use Indicated for Adults with End-Stage Renal Disease (ESRD) on dialysis for reducing serum phosphorus.
Absolute Contraindication Patients with Hypercalcemia (high levels of calcium in the blood) must not use Marcal.
Pediatric Eligibility Use Not Established in the pediatric population (children and adolescents), as safety and effectiveness have not been defined.
Conditional/Restricted Use Use requires caution in Older Adults (dose selection should be cautious) and is restricted for patients taking Digitalis (Digoxin) or those using other calcium supplements.

Pregnancy and Lactation Eligibility

  • Pregnancy: Use is permitted only if clearly needed, and requires careful monitoring of maternal calcium levels.
  • Lactation: Use is generally acceptable, provided that maternal serum calcium levels are appropriately monitored.

What should I know about interactions with other medicines?

Marcal’s official interaction profile, as defined by government regulatory documents, is characterized by two distinct mechanisms: physical binding and additive calcium effects.

Exposure Modification and Timing Rules

The medication may substantially decrease the systemic exposure to certain co-administered oral medicines. This pharmacokinetic interaction is formally documented for the antibiotic classes of tetracyclines and fluoroquinolones, as well as the thyroid hormone levothyroxine. This decrease in bioavailability is due to the formation of insoluble complexes in the gastrointestinal tract. To mitigate this effect, official timing constraints are mandated: for example, levothyroxine requires separation by at least four hours from Marcal administration. Fluoroquinolones must be separated by at least two hours before or six hours after Marcal.

Additive Risk and Restrictions

Marcal is a source of elemental calcium, contributing to the risk of hypercalcemia. The use of the medication is formally contraindicated in patients with pre-existing high blood calcium levels. This potential for hypercalcemia necessitates specific restrictions: co-administration of digitalis (digoxin) carries an official warning, as elevated calcium levels may aggravate digitalis toxicity. Furthermore, official labeling advises against the concurrent use of calcium supplements, including non-prescription antacids, due to the risk of an additive calcium load.

Mechanism of Action

Intraluminal Chemical Binding of Dietary Phosphate

This mechanism defines the non-systemic interaction of Calcium Acetate with its target. The action initiates with the rapid dissociation of the salt in the small intestine, releasing Calcium ions ( Ca^2+). These ions directly engage in a chemical precipitation reaction with the Dietary Phosphate ( PO4^3-) derived from food.


Interruption of the Enteric Absorption Pathway

The chemical binding creates a highly insoluble Calcium Phosphate complex ( Ca3( PO4)2). This complex cannot be absorbed across the intestinal wall, functionally interrupting the natural enteric absorption pathway for phosphate. The non-absorbable precipitate is then eliminated via the feces, resulting in a net reduction of the phosphate load entering the systemic circulation, which results in the modulation of the concentration of phosphate in the systemic circulation.


⏳ Context-Dependent Mechanistic Kinetics

The functional capacity of the mechanism is strictly tied to co-localization with its target, requiring the Ca^2+ ions to be present at the same time as the dietary phosphate. The high solubility of Calcium Acetate across the intestinal pH range ensures the rapid availability of the binding agent, facilitating the interruption of the absorption pathway during the transient window of dietary phosphate availability.

Dosage and Administration Information

How Marcal is Used: Administration Guidelines

Marcal, which contains the active ingredient Calcium Acetate, is strictly an oral medication available as capsules, tablets, or liquid solution. Its administration is entirely dependent on food intake and is intended for chronic, long-term use as part of a mineral management plan.


Dosing and Administration Schedule

Feature Instruction
Administration Route Oral use only.
Dosing Frequency Administered with each meal (e.g., three times per day).
Initial Adult Dose Typically begins at 1334 mg (e.g., two 667 mg units) per meal.
Dose Adjustment The amount is titrated (adjusted) every 2 to 3 weeks based on monitored lab results.
Missed Dose Rule If a dose is missed, it should be skipped. The normal schedule is resumed with the next meal; a double dose is not to be taken.

Administration Conditions and Constraints

The required timing of Marcal with meals ensures that the drug is present in the gastrointestinal tract when dietary phosphorus is consumed.

Special Procedural Conditions: When administering the oral solution form, the dose must be measured precisely using a calibrated device. To avoid interference with absorption, Marcal must be taken separate from certain other oral medications, typically by at least one hour before or three hours after the other drug.

Population Considerations: For older adults, dose selection is typically cautious, often starting at the lower end of the adult dosing range. The safety and effectiveness of Marcal in pediatric patients have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research has explored whether the combination affects lung function and symptoms. Clinical trials have primarily focused on adults diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and asthma. The studies ranged in duration from 4 to 26 weeks, with most being randomized, placebo-controlled trials.

  • Studies have evaluated whether the drug combination can affect lung capacity in patients with COPD. These trials measured forced expiratory volume in one second (FEV1).
  • Studies examined whether the drug combination was associated with changes in reported pain and inflammation.
  • Research evaluated the speed of action and any effect on acute asthma symptoms.

Key Study Findings

1. Lung Function and Exacerbations

In trials involving patients with moderate to severe COPD:

  • An analysis of 12 randomized controlled trials (RCTs) involving over 6,000 participants reported a change in the frequency of flare-ups over a 12-week period.
  • Research explored whether the combination was associated with a change in the need for rescue medication.
  • Findings regarding the combination's effect on improving FEV1 were mixed across different study populations.

2. Safety and Side Effects

Reported adverse events were evaluated during the studies.

  • Subgroup analysis included evaluation of the drug combination in elderly patients.
  • Studies examined the use of the drug combination in people with heart conditions.
  • Research compared the combination to monotherapy in managing chronic bronchitis. Adverse event rates for the combination group were compared against those for the monotherapy group in the reviewed studies.

Limitations of the Evidence

Evidence remains limited regarding the long-term effects (beyond 6 months) and use in pediatric populations.

Key Studies & References

  1. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score
  2. Real-world Effectiveness of Combination Therapy in Asthma (NCT01141465)

Frequently Asked Questions (FAQ)

Common questions about Marcal (FAQ)


Q: What should I do if I forget to take my Marcal dose one day?

Official administration instructions indicate that a missed dose should be skipped. The normal dosing schedule should be resumed with the next meal. Official documents state that a double dose is not to be taken to make up for a missed one.


Q: Can older adults use Marcal, or are there special precautions?

Regulatory documents state that use in older adults is permitted. However, the official product information advises that dose selection should be cautious, often starting at the lower end of the adult dosing range. Dose selection should be approached with caution.


Q: What are the most commonly reported less serious side effects of Marcal?

According to official regulatory documents, the most common documented adverse effects include hypercalcemia (elevated calcium levels), nausea, and diarrhea. Vomiting is also listed as a common adverse reaction in clinical trial reports.


Q: How long does it usually take to feel the effects of Marcal?

The drug's action of chemically binding phosphate occurs at the time of co-localization with food. The overall therapeutic effect is measured by monitoring blood test results, which usually leads to dose adjustment every two to three weeks until the desired level is reached.


Q: Why is Marcal prescribed to people with different health issues?

Official regulatory documents indicate that Marcal is approved for reducing serum phosphorus levels in adults with End-Stage Renal Disease (ESRD) who are on dialysis. Research has also examined the drug's effects in studies involving conditions like COPD and asthma, which may be why the drug is discussed in connection with these conditions.


Q: Is Marcal the same type of medicine as [similar drug name]?

Marcal is a prescription oral medication classified in regulatory documents as a Phosphate Binder. This classification defines its specific action, which is to bind phosphate from food within the gastrointestinal tract.


Q: Is it common to feel tired when first starting Marcal?

While tiredness is not listed as a common side effect itself, post-approval adverse reaction reports have included dizziness and weakness. Severe hypercalcemia (high blood calcium), a serious risk, is officially associated with symptoms that include a tired feeling and lack of energy.


Q: Can Marcal be taken at the same time as cold medicine?

Official guidelines recommend that Marcal must be taken separately from certain other oral medications due to the potential for absorption interference. This separation is typically specified as at least one hour before or three hours after the other drug.


Q: What kind of studies have been done on Marcal?

The evidence base for Marcal includes randomized, placebo-controlled trials (RCTs). These studies primarily focused on adults and have included evaluations of lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma.


Q: Do I need to change my diet while taking Marcal?

The drug's action is reliant on binding dietary phosphate, and it is administered with each meal to support its effectiveness. Regulatory documents do not mandate comprehensive diet changes, but the required timing with food is critical for its function.


Q: Is Marcal known to cause long-term side effects?

Official regulatory documents note that long-term exposure to hypercalcemia, a very common side effect, may contribute to chronic issues. These issues include vascular and soft-tissue calcification (the buildup of calcium in blood vessels and tissues).


Q: What are the main things to avoid when taking Marcal?

The medication is formally contraindicated (must not be used) if high levels of calcium are present in the blood (hypercalcemia). Concurrent use with other calcium supplements is advised against. Specific timing rules are also mandated for certain co-administered oral medicines.


Q: Are there any religious or dietary restrictions related to Marcal ingredients?

The active ingredient in Marcal is Calcium Acetate, which is classified as a synthetic inorganic salt. Official regulatory documents do not list any religious or non-medical dietary restrictions related to its chemical composition.


Q: What if I have an allergic reaction to Marcal?

While rare, postmarketing experience has identified isolated cases of pruritus (itching) which may represent allergic reactions. Official labeling states that seeking prompt medical attention is necessary if a serious adverse reaction occurs.


Q: Is it safe to drive or operate machinery while taking Marcal?

Adverse reactions reported in regulatory documents include dizziness. Furthermore, severe hypercalcemia, a serious potential side effect, is associated with central nervous system effects such as confusion and delirium, which are symptoms associated with impaired judgment.


Q: What if I'm taking herbal products? Do they interact with Marcal?

Regulatory advice states that patients should inform their healthcare provider about all products they are taking. This includes prescription and nonprescription medicines, vitamins, nutritional supplements, and any herbal products.


Q: What is the typical duration of treatment with Marcal?

Marcal is described in official administration guidelines as being intended for chronic, long-term use. Its purpose is to be part of an ongoing mineral management plan to help control serum phosphorus concentrations.


Q: Is there a generic version of Marcal available?

The active ingredient, Calcium Acetate, is available under multiple brand names. Its regulatory status includes Abbreviated New Drug Application (ANDA) information, which is the process used for the approval of generic drugs.


Q: How is Marcal different from older medicines used for the same purpose?

Marcal is a phosphate binder classified as a synthetic inorganic salt. It acts via a non-systemic mechanism—chemically binding dietary phosphate within the gastrointestinal tract—rather than acting systemically in the bloodstream.


Q: Are the effects of Marcal permanent after I stop taking it?

The drug’s action is defined as a non-systemic chemical binding reaction that is strictly dependent on the drug being present at the same time as the dietary phosphate. This means the effect ceases once the medication is no longer being administered with food.


Q: Are there any foods that specifically enhance or reduce Marcal's effectiveness?

The medication must be administered with each meal because its binding action is strictly tied to co-localization with dietary phosphate. No specific foods are mentioned in regulatory documents as enhancing or reducing its effectiveness, beyond the need to take it with food.


Q: How does Marcal affect the metabolism?

Adverse reactions documented in regulatory documents are classified under the official System-Organ Class of Metabolism and Nutrition Disorders, which points to the drug's role in mineral equilibrium.


Q: Does Marcal have any psychoactive effects?

The drug is not classified as psychoactive. However, severe hypercalcemia, a serious adverse reaction, is associated with central nervous system effects including confusion, delirium, stupor, and coma.


Q: Is Marcal a controlled substance?

According to the U.S. regulatory information, the product is classified as a Human Prescription Drug with a DEA Schedule of None. This indicates it is not considered a controlled substance.

How should Marcal be stored and disposed of?

How to Store and Dispose of Marcal (Calcium Acetate)

The medication must be stored according to specific regulatory conditions to maintain its stability. Marcal (Calcium Acetate) should be kept at Controlled Room Temperature, defined as 20° to 25°C (68° to 77°F), and kept from freezing. The container must be stored in a dry place and tightly closed to protect the hygroscopic medicine from moisture and heat. It is a mandatory requirement to store the medication out of the reach of children and in its original container.

Disposal Requirements

Do not keep outdated medicine. The product must not be disposed of together with household garbage or released into the sewage system. Users should ask a healthcare professional or pharmacist about the correct procedures for disposing of any unused or expired medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Marcal found in:

A-Z Index: